Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine

Journal of Pediatric Endocrinology and Metabolism

Volumn 11, Issue SUPPL. 3, 1998, Pages 827-833

  De Sanctis, V ^a,e   Stea, S ^b   Savarino, L ^b   Scialpi, V ^a   Traina, G G ^c   Chiarelli, G M ^c   Sprocati, M ^a   Govoni, R ^a   Pezzoli, D ^a   Gamberini, R ^a   Rigolin, F ^d  

^a Arcispedale St Anna ^*  (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d Arcispedale St Anna   (Italy)

^e UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Bone lesions; GH insufficiency; Skeletal dysplasia; Thalassaemia

Indexed keywords

DEFEROXAMINE; GROWTH HORMONE;

ADOLESCENT; BONE DYSPLASIA; BONE LESION; BONE MINERALIZATION; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH RETARDATION; HISTOLOGY; HUMAN; IRON CHELATION; MALE; SCHOOL CHILD; THALASSEMIA;

ADOLESCENT; BETA-THALASSEMIA; BIOPSY; BONE AND BONES; BONE DISEASES, DEVELOPMENTAL; CARTILAGE; CHILD; CHONDROCYTES; DEFEROXAMINE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; ILIUM; IRON CHELATING AGENTS; MALE; TIBIA;

EID: 0032424336     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, Vullo C. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Paediatr 1996; 155: 368-372.
2. De Sanctis V, Atti G, Banin P, Orzincolo C, Cavallini AR, Patti D, Vullo C. Growth in thalassaemia major. Acta Med Auxol 1991; 23: 29-36.
3. De Virgilis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Fodde M, Pirastu GF, Cao A. Desferrioxamine-induced growth retardation in patients with thalassaemia major. J Pediatr 1988; 113: 661-669.
4. Brill PW, Winchester P, Giardina PI, Cunnigham-Rundles S. Desferrioxamine induced bone dysplasia in patients with thalassaemia major. AJR 1991; 156: 561-565.
5. Hatori M, Sparkman J, Teixeira CC, Grynpas M, Nervina J, Olivieri N, Shapiro IM. Effects of deferioxamine on chondrocyte alkaline phosphatase activity: proxidant role of deferioxamine in thalassaemia. Calc Tissue Int 1995; 57: 229-236.
6. De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B. Effect of different treatment regimes on linear growth and final height. Clin Endocrinol 1994; 40: 791-798.
7. Arcasoy A, Cavdar A, Cin S, Erten J, Babacan E, Gozdasoglu S, Acar N. Effects of zinc supplementation on linear growth in beta-thalassaemia (a new approach). Am J Hematol 1987; 24: 127-136.
8. Cunningham BC, Bass S, Futi G. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 1990; 250: 1709-1712.
9. Slonim AE, Sadick N, Pugliese M, Meyers-Seifer C. Clinical response of alopecia, trichonhexis nodosa and dry, scaly skin to zinc supplementation. J Pediatr 1992; 121: 890-895.
10. De Sanctis V, Urso L, Galati MC, Mangiagli A, Massolo L, Ponzi G, Ruggiero L, Sacco M, Cavallini AR, Rigolin F. Growth hormone (GH) treatment in thalassaemic patients with short stature, GH insufficiency and different severity of iron overload. Bone Marrow Transpl 1997; 19 (Suppl): 32.
11. Genge BR, Sauer GR, Wu LNY, McLean FM, Wutier RE. Correlation between loss of alkaline phosphatase activity and accumulation of calcium during matrix vescicle-mediated mineralization. J Biol Chem 1988; 263: 18513-18519.